title: Sustained and expedited resolution of diabetic papillopathy with combined PRP and bevacizumab.
authors.affiliation: University of Iowa, Iowa City, Iowa. Electronic address: chin.eric@gmail.com.
authors.forename: Eric K
authors.initials: EK
authors.lastname: Chin
authors.affiliation: University of Iowa, Iowa City, Iowa.
authors.forename: David R P
authors.initials: DR
authors.lastname: Almeida
authors.affiliation: University of Iowa, Iowa City, Iowa.
authors.forename: Elliott H
authors.initials: EH
authors.lastname: Sohn
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D010211:Papilledema / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab